NCT06664411招募中2 期
Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
Navy General Hospital, Beijing1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2024年9月24日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Progression Free Survival (PFS)
研究概览
简要总结
The goal of this phase 2 trial is to test the safety and efficacy of Pola-ZR2P as induction therapy in patients with DLBCL.
详细描述
The investigators will evaluate safety and efficacy of Pola-ZR2P as induction therapy in Previously Untreated Diffuse Large B-Cell Lymphoma. ORR(Overall response rate, progression-free survival (PFS), overall survival (OS), adverse events (AEs) will be assessed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 14 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically confirmed Diffuse Large B Cell Lymphoma according World Health Organization (WHO) classification;
- •Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).
- •Patient must understand and voluntarily sign an ICF prior to any study-specific assessments/procedures being conducted;
- •Patient is willing and able to adhere to the study visit schedule and other protocol requirements;
- •Patient has not received chemotherapy previously.
- •Anticipated life expectancy at least 3 months
排除标准
- •Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.
- •Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.
- •Pregnant or lactating women
研究组 & 干预措施
Pola-ZR2P
Experimental
Patients were treated by Pola-ZR2P as Induction Therapy
干预措施: Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy (Drug)
结局指标
主要结局
Progression Free Survival (PFS)
时间窗: 2 years
Progression was defined according to the Lugano Response Criteria
次要结局
- Overall Survival (OS)(through study completion, an average of 2 years)
- Overall Response Rate (ORR)(1 year)
研究者
Liren Qian
Associate Chief Physician, Associate Professor
Navy General Hospital, Beijing
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
G-Pola-ZLP in Diffuse Large B-Cell LymphomaDiffuse Large B-Cell LymphomaNCT06665217Navy General Hospital, Beijing80
终止
2 期
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell LymphomaDiffuse Large B-cell LymphomaNCT05498220UNC Lineberger Comprehensive Cancer Center5
招募中
2 期
A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell LymphomaLarge B-cell LymphomaNCT06071871University College, London99
进行中（未招募）
2 期
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3a Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Grade 1 Follicular LymphomaRefractory Grade 2 Follicular LymphomaRefractory Grade 3a Follicular LymphomaRefractory Mantle Cell LymphomaRefractory Marginal Zone LymphomaRefractory Small Lymphocytic LymphomaNCT04659044Academic and Community Cancer Research United63
尚未招募
2 期
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCLDiffuse Large B-cell LymphomaNCT06503263Navy General Hospital, Beijing240